Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.
Greene AJE, Davis J, Moon J, Dubin I, Cruz A, Gupta M, Moazzez A, Ozao-Choy J, Gupta E, Manchandia T, Kalantari BN, Rahbar G, Dauphine C. Greene AJE, et al. Among authors: kalantari bn. Ann Surg Oncol. 2024 May;31(5):3177-3185. doi: 10.1245/s10434-024-15041-1. Epub 2024 Feb 22. Ann Surg Oncol. 2024. PMID: 38386195 Free PMC article.
Corrigendum to "Assessing the effectiveness of artificial neural networks (ANN) and multiple linear regressions (MLR) in forecasting AQI and PM10 and evaluating health impacts through AirQ+ (case study: Tehran)" [Environ. Pollut., 338 (2023) 122623].
Shams SR, Kalantary S, Jahani A, Parsa Shams SM, Kalantari B, Singh D, Moeinnadini M, Choi Y. Shams SR, et al. Among authors: kalantari b. Environ Pollut. 2024 Feb 1;342:123102. doi: 10.1016/j.envpol.2023.123102. Epub 2023 Dec 12. Environ Pollut. 2024. PMID: 38086164 No abstract available.
Assessing the effectiveness of artificial neural networks (ANN) and multiple linear regressions (MLR) in forcasting AQI and PM10 and evaluating health impacts through AirQ+ (case study: Tehran).
Shams SR, Kalantary S, Jahani A, Parsa Shams SM, Kalantari B, Singh D, Moeinnadini M, Choi Y. Shams SR, et al. Among authors: kalantari b. Environ Pollut. 2023 Dec 1;338:122623. doi: 10.1016/j.envpol.2023.122623. Epub 2023 Oct 6. Environ Pollut. 2023. PMID: 37806430
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, Bary A, Mirzania M, Haghighat S, Razavi SM, Emami SAH, Hosseinzadeh M, Mirbolouk M, Sadighi S, Shahrasbi A, Esfahani A, Gity M, Anjidani N, Kaf H, Najaf S. Allahyari A, et al. Among authors: kalantari b. BMC Cancer. 2022 Dec 22;22(1):1348. doi: 10.1186/s12885-022-10455-0. BMC Cancer. 2022. PMID: 36550442 Free PMC article. No abstract available.
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, Bary A, Mirzania M, Haghighat S, Razavi SM, Emami SAH, Hosseinzadeh M, Mirbolouk M, Sadighi S, Shahrasbi A, Esfahani A, Gity M, Anjidani N, Kafi H, Najafi S. Allahyari A, et al. Among authors: kalantari b. BMC Cancer. 2022 Sep 7;22(1):960. doi: 10.1186/s12885-022-09895-5. BMC Cancer. 2022. PMID: 36071409 Free PMC article. Clinical Trial.
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS, Kalantari B, Raafat J, Ansarinejad N, Moazed V, Mortazavizadeh SMR, Hosseinzadeh M, Ghaderi B, Jenabian A, Qadyani M, Haghighat S, Allahyari A, Mirzania M, Seghatoleslami M, Payandeh M, Alikhasi A, Kafi H, Shahi F. Nodehi RS, et al. Among authors: kalantari b. BMC Pharmacol Toxicol. 2022 Jul 28;23(1):57. doi: 10.1186/s40360-022-00599-x. BMC Pharmacol Toxicol. 2022. PMID: 35902898 Free PMC article. Clinical Trial.
Squamous Cell Carcinoma Arising in Breast Implant Capsules.
Goldberg MT, Llaneras J, Willson TD, Boyd JB, Venegas RJ, Dauphine C, Kalantari BN. Goldberg MT, et al. Among authors: kalantari bn. Ann Plast Surg. 2021 Mar 1;86(3):268-272. doi: 10.1097/SAP.0000000000002524. Ann Plast Surg. 2021. PMID: 32804719
β-radiating radionuclides in cancer treatment, novel insight into promising approach.
Asadian S, Mirzaei H, Kalantari BA, Davarpanah MR, Mohamadi M, Shpichka A, Nasehi L, Es HA, Timashev P, Najimi M, Gheibi N, Hassan M, Vosough M. Asadian S, et al. Among authors: kalantari ba. Pharmacol Res. 2020 Oct;160:105070. doi: 10.1016/j.phrs.2020.105070. Epub 2020 Jul 10. Pharmacol Res. 2020. PMID: 32659429 Review.
28 results